ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Exelixis, Bristol-Myers Squibb and Ipsen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Exelixis×Bristol-Myers Squibb×Ipsen×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

ExelixisBristol-Myers SquibbIpsen
studies on the registry572,184358
open to participants now1115625
phase 3 studies under way108216
reach primary completion within a year66916
programswith a study of their own in two years458+9 named only9

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseExelixisBristol-Myers SquibbIpsen
Phase 150%

Bristol-Myers Squibb: 17 of its 58 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

29%

Ipsen: 1 of its 9 programs at phase 1

  1. tovorafenibphase 1
11%
Phase 200%

Bristol-Myers Squibb: 18 of its 58 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 13 more — sign in to see them all

31%
44%
Phase 3

Exelixis: 1 of its 4 programs at phase 3

  1. zanzalintinibphase 3
25%

Bristol-Myers Squibb: 16 of its 58 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

Ipsen: 4 of its 9 programs at phase 3

  1. corabotasephase 3
  2. elifibranorphase 3
  3. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3
  4. Palovarotenephase 3
44%
Approved, new studies

Exelixis: 1 of its 4 programs at approved, new studies

  1. cabozantinibapproved, new study
25%

Bristol-Myers Squibb: 7 of its 58 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Exelixis2 readouts · 1 phase 3·

Exelixis, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zanzalintinibphase 3 · Dec 15 · NCT05678673
····

Exelixis, May ’27: 1 program whose next study reaches primary completion

  1. Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628phase 1 · May 31 · NCT06952010
·····
Bristol-Myers Squibb23 readouts · 8 phase 3

Bristol-Myers Squibb, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. deucravacitinibapproved, new study · Nov 18 · NCT05946941
  2. trospiumapproved, new study · Nov 24 · NCT06585787
  3. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. trospium chlorideapproved, new study · Dec 3 · NCT07204418
  3. navlimetostatphase 3 · Dec 5 · NCT07777133
  4. delocamtenphase 2 · Dec 14 · NCT06122779
  5. golcadomidephase 3 · Dec 14 · NCT07763418

and 3 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836
··

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
Ipsen3 readouts · 2 phase 3·

Ipsen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. corabotasephase 3 · Dec 15 · NCT07435428
  2. elifibranorphase 3 · Dec 17 · NCT06730061
·········

Ipsen, Oct ’27: 1 program whose next study reaches primary completion

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3 · Oct 15 · NCT04243499
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Exelixis

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10 · Carcinoma, Non-Small-Cell Lung
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Ipsen

New programs 1

  • IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionExelixisBristol-Myers SquibbIpsen
Neoplasm Metastasisall three · compare here

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Exelixis in Carcinoma, Non-Small-Cell Lung: 1 program

  1. zanzalintinibphase 3

Their studies: Exelixis’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 12 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 7 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Colorectal Neoplasms2 of 3 · compare here

Exelixis in Colorectal Neoplasms: 1 program

  1. zanzalintinibphase 3

Their studies: Exelixis’s studies of Colorectal Neoplasms in search

Bristol-Myers Squibb in Colorectal Neoplasms: 5 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Anti-CEACAM5 Antibody-drug Conjugate BMS-986490phase 2
  4. BMS-986488phase 1
  5. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

–
Carcinoma, Hepatocellular2 of 3 · compare here

Exelixis in Carcinoma, Hepatocellular: 1 program

  1. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Carcinoma, Hepatocellular in search

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

–
Carcinoma, Renal Cell2 of 3 · compare here

Exelixis in Carcinoma, Renal Cell: 2 programs

  1. zanzalintinibphase 3
  2. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Carcinoma, Renal Cell in search

Bristol-Myers Squibb in Carcinoma, Renal Cell: 3 programs

  1. BMS-986527phase 1
  2. Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506phase 1
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Renal Cell in search

–
Neoplasms2 of 3 · compare here

Exelixis in Neoplasms: 2 programs

  1. zanzalintinibphase 3
  2. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Neoplasms in search

Bristol-Myers Squibb in Neoplasms: 3 programs

  1. BMS-986500phase 1
  2. Digoxinphase 1
  3. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

–
Prostatic Neoplasms2 of 3 · compare here

Exelixis in Prostatic Neoplasms: 1 program

  1. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Prostatic Neoplasms in search

Bristol-Myers Squibb in Prostatic Neoplasms: 3 programs

  1. dezandrodegphase 3
  2. RYZ711phase 2
  3. orevandrodegphase 1

Their studies: Bristol-Myers Squibb’s studies of Prostatic Neoplasms in search

–
Melanoma2 of 3 · compare here–

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

Ipsen in Melanoma: 1 program

  1. tovorafenibphase 1

Their studies: Ipsen’s studies of Melanoma in search

Glioblastoma2 of 3 · compare here

Exelixis in Glioblastoma: 1 program

  1. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Glioblastoma in search

Bristol-Myers Squibb in Glioblastoma: 1 program

  1. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Glioblastoma in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetExelixisBristol-Myers SquibbIpsen
CD274Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628rulepumitamig–
A target, or a pathogen for a vaccine, known for: Exelixis 4 of 4 · Bristol-Myers Squibb 33 of 58 · Ipsen 4 of 9 programs (24 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9).